DexCom, Inc. (NASDAQ:DXCM) Stake Lessened by NorthCrest Asset Manangement LLC

NorthCrest Asset Manangement LLC lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 24,939 shares of the medical device company’s stock after selling 1,137 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in DexCom were worth $1,672,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom during the 2nd quarter valued at $25,000. Sachetta LLC grew its position in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the last quarter. Crewe Advisors LLC bought a new position in shares of DexCom in the first quarter worth about $29,000. Riverview Trust Co lifted its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the last quarter. Finally, DT Investment Partners LLC lifted its position in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of research analyst reports. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a report on Friday. Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. Piper Sandler restated an “overweight” rating and issued a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Stifel Nicolaus upped their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Finally, Robert W. Baird lifted their target price on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Six equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $104.59.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,824 shares of company stock worth $126,390. 0.30% of the stock is currently owned by insiders.

DexCom Trading Down 1.9 %

Shares of DexCom stock opened at $73.44 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The stock has a market capitalization of $29.43 billion, a P/E ratio of 45.33, a price-to-earnings-growth ratio of 2.26 and a beta of 1.18. The company has a 50-day simple moving average of $70.11 and a 200 day simple moving average of $98.24. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 24th. The medical device company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.02. The company had revenue of $994.20 million during the quarter, compared to analyst estimates of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. Research analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.